JP7175760B2 - 新規なｉｇｆｒ様レセプター及びその使用 - Google Patents

新規なｉｇｆｒ様レセプター及びその使用 Download PDF

Info

Publication number
JP7175760B2
JP7175760B2 JP2018512274A JP2018512274A JP7175760B2 JP 7175760 B2 JP7175760 B2 JP 7175760B2 JP 2018512274 A JP2018512274 A JP 2018512274A JP 2018512274 A JP2018512274 A JP 2018512274A JP 7175760 B2 JP7175760 B2 JP 7175760B2
Authority
JP
Japan
Prior art keywords
igfr
receptor
insulin
receptors
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528213A5 (https=
JP2018528213A (ja
Inventor
リッケルト，ハイコ
Original Assignee
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） filed Critical ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Publication of JP2018528213A publication Critical patent/JP2018528213A/ja
Publication of JP2018528213A5 publication Critical patent/JP2018528213A5/ja
Priority to JP2022179426A priority Critical patent/JP7807359B2/ja
Application granted granted Critical
Publication of JP7175760B2 publication Critical patent/JP7175760B2/ja
Priority to JP2025132452A priority patent/JP2025166096A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
JP2018512274A 2015-09-07 2016-09-07 新規なｉｇｆｒ様レセプター及びその使用 Active JP7175760B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022179426A JP7807359B2 (ja) 2015-09-07 2022-11-09 新規なｉｇｆｒ様レセプター及びその使用
JP2025132452A JP2025166096A (ja) 2015-09-07 2025-08-07 新規なｉｇｆｒ様レセプター及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92818 2015-09-07
LU92818 2015-09-07
PCT/EP2016/071126 WO2017042242A1 (en) 2015-09-07 2016-09-07 Novel igfr-like receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022179426A Division JP7807359B2 (ja) 2015-09-07 2022-11-09 新規なｉｇｆｒ様レセプター及びその使用

Publications (3)

Publication Number Publication Date
JP2018528213A JP2018528213A (ja) 2018-09-27
JP2018528213A5 JP2018528213A5 (https=) 2019-09-19
JP7175760B2 true JP7175760B2 (ja) 2022-11-21

Family

ID=54337321

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018512274A Active JP7175760B2 (ja) 2015-09-07 2016-09-07 新規なｉｇｆｒ様レセプター及びその使用
JP2022179426A Active JP7807359B2 (ja) 2015-09-07 2022-11-09 新規なｉｇｆｒ様レセプター及びその使用
JP2025132452A Withdrawn JP2025166096A (ja) 2015-09-07 2025-08-07 新規なｉｇｆｒ様レセプター及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022179426A Active JP7807359B2 (ja) 2015-09-07 2022-11-09 新規なｉｇｆｒ様レセプター及びその使用
JP2025132452A Withdrawn JP2025166096A (ja) 2015-09-07 2025-08-07 新規なｉｇｆｒ様レセプター及びその使用

Country Status (8)

Country Link
US (1) US20190248905A1 (https=)
EP (2) EP3896080A1 (https=)
JP (3) JP7175760B2 (https=)
CN (1) CN108026160A (https=)
DK (1) DK3347376T3 (https=)
ES (1) ES2862175T3 (https=)
PL (1) PL3347376T3 (https=)
WO (1) WO2017042242A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3096533C (en) 2018-04-27 2023-08-29 Aimed Bio Inc. Magnetic-based biopanning method through attachment of magnetic bead to cell
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
EP4373855A1 (en) 2021-07-23 2024-05-29 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Igfr-l1 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017563A1 (en) 1997-03-31 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20070065448A1 (en) * 2005-07-06 2007-03-22 Applera Corporation Methods and compositions for treating diseases targeting MABA1
US20110229480A1 (en) * 2008-09-04 2011-09-22 Oxford Biotherapeutics Ltd Pta072 protein
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017563A1 (en) 1997-03-31 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
JP2023015235A (ja) 2023-01-31
ES2862175T3 (es) 2021-10-07
JP2025166096A (ja) 2025-11-05
EP3896080A1 (en) 2021-10-20
EP3347376A1 (en) 2018-07-18
JP7807359B2 (ja) 2026-01-27
CN108026160A (zh) 2018-05-11
US20190248905A1 (en) 2019-08-15
JP2018528213A (ja) 2018-09-27
EP3347376B1 (en) 2021-01-06
PL3347376T3 (pl) 2021-12-06
WO2017042242A1 (en) 2017-03-16
DK3347376T3 (da) 2021-03-29

Similar Documents

Publication Publication Date Title
JP7807359B2 (ja) 新規なｉｇｆｒ様レセプター及びその使用
US20140303078A1 (en) Modulation of pancreatic beta cell proliferation
US8383602B2 (en) Use of TRIM72 as a target for muscle and heart enhancer
WO2010131704A1 (ja) 内臓脂肪型肥満の検査薬およびその利用
CN106456700B (zh) 糖尿病治疗和预防的新靶标
WO2002053738A1 (fr) Nouvelles proteines et adn correspondant
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
US12583928B2 (en) Antibodies against IGFR-like receptor and uses thereof
US20250282849A1 (en) Fndc4 fusion protein and uses thereof
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
US7700361B2 (en) Secretory or membrane protein expressed in skeletal muscles
US20110104705A1 (en) Musclin receptor and use thereof
US20090170773A1 (en) Novel use of g-protein-conjugated receptor and ligand thereof
JP4559775B2 (ja) 新規蛋白質
CN117980340A (zh) Igfr-l1抗体及其用途
JP2024529411A (ja) Ｉｇｆｒ－ｌ１抗体およびその使用
JP2006298798A (ja) マスクリン受容体およびその用途
WO2004044199A1 (ja) スクリーニング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221109

R150 Certificate of patent or registration of utility model

Ref document number: 7175760

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250